The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

Multiple Myeloma Clinical Trial

Official title:

A Phase III Study to Determine the Role of Ixazomib as an Augmented Conditioning Therapy in Salvage Autologous Stem Cell Transplant (ASCT) and as a Post-ASCT Consolidation and Maintenance Strategy in Patients With Relapsed Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03562169
• Other study ID #: HM16/047
• Secondary ID: 2016-000905-35
• Status: Recruiting
• Phase: Phase 3
• Start date: March 20, 2017
• Est. completion date: March 2027

Study information

• Verified date: May 2018
• Source: University of Leeds
• Contact: Gwen Jacques, Senior Trial Coordinator
• Phone: 0044 113 343 1159
• Email: ctru-myelomaxii[@]leeds.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study design: Randomised, controlled, multi-centre, open-label, phase III trial (with a single intervention registration phase).

Primary Objectives

The primary objectives of this study are to determine:

• The impact on Depth of Response (DoR: less than VGPR versus VGPR or better) when salvage ASCT conditioning is augmented by the addition of a proteasome inhibitor

• The influence of a consolidation and maintenance strategy on the Durability of Response (DuR:PFS)

Secondary objectives

The secondary objectives of this study are to determine:

• Overall survival

• Time to disease progression

• The overall response rate following ixazomib, thalidomide and dexamethasone (ITD) re-induction

• Time to next treatment

• Progression-free survival 2 (PFS2)

• Duration of response

• Minimal Residual Disease (MRD) negative rate post re-induction, post-ASCT and conversion after ITD consolidation

• Engraftment kinetics

• Toxicity and safety

• Quality of life (QoL)

Participant population (refer to protocol section 9 for a full list of eligibility criteria).

• Relapsed MM (with measurable disease by IMWG criteria) previously treated with ASCT

• First progressive disease (PD) at least 12 months since first ASCT, requiring therapy.

• ECOG Performance Status 0-2

• Aged at least 18 years

• Adequate full blood count and renal, hepatobiliary, pulmonary and cardiac function

• Written informed consent

Interventions: All participants will be registered at trial entry and will receive re-induction therapy with 4-6, 28-day cycles of ixazomib, thalidomide and dexamethasone (ITD), in order to reach maximum response. Participants who achieve at least stable disease (SD) will be randomised on a 1:1 basis to receive either conventional ASCT (ASCTCon), using melphalan, or augmented ASCT (ASCTAug), using melphalan with ixazomib. All participants achieving or maintaining a minimal response (MR) or better following trial ASCT will undergo a second randomisation to consolidation and maintenance or no further treatment. Participants randomised to consolidation and maintenance will receive treatment as follows: consolidation with 2 cycles of ITD and maintenance with ixazomib until disease progression.

Number of participants: 406 participants will be registered into the trial to allow 284 participants to be randomised at the first randomisation (R1) and 248 participants to be randomised at the second randomisation (R2).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 406
• Est. completion date: March 2027
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Diagnosed with relapsed MM (with measurable disease, according to IMWG criteria (Appendix 2)) previously treated with ASCT).

2. First Progressive Disease (PD) at least 12 months following first ASCT, requiring therapy.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 (Appendix 3).

4. Aged at least 18 years.

5. Participants must have the following blood results within 14 days before registration:

1. Absolute neutrophil count (ANC) =1x109/L

2. Platelet count =75x109/L. If the participant has =50% bone marrow infiltration a platelet count of =50x109/L is allowed.

Platelet transfusions are not allowed within 3 days before registration in order to meet these values.

6. Adequate renal function within 14 days before registration:

a. Creatinine clearance =30ml/min (calculated according to the Cockcroft-Gault equation or other locally approved formula)

7. Adequate hepatobiliary function within 14 days before registration:

1. Total bilirubin <2 x upper limit of normal (ULN)

2. ALT <2 x ULN

8. Adequate pulmonary function within 14 days before registration:

a. Adequate respiratory functional reserve (delineated by KCO/DLCO (carbon monoxide diffusion in the lung) of =50%). No evidence of a history of pulmonary disease. If a significant history, then a review by a respiratory medicine physician is required.

9. Adequate cardiac function within 12 weeks before registration

a. Left ventricular ejection fraction (LVEF) =40%. Note: repeat confirmation of cardiac function is needed if treatment is given between this assessment and registration.

10. Female participants who:

1. Are not of childbearing potential (Appendix 8), OR

2. If they are of childbearing potential (Appendix 8), agree to practice 2 effective methods of contraception (Appendix 8), at the same time, from the time of signing the informed consent form until 90 days after the last dose of study drug, OR

3. Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

Male participants, even if surgically sterilised (i.e. status post-vasectomy), must agree to one of the following:

1. Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR

2. Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.) Contraception for female and male participants must be in accordance with (and consent to) the Celgene-approved Thalidomide Pregnancy Prevention Programme.

11. If female and of childbearing potential (see Appendix 8), must have a negative pregnancy test performed by a healthcare professional in accordance with the Celgene Thalidomide Pregnancy Prevention Programme.

12. Patients agree not to receive other clinical trials treatment, including investigational medicinal products (IMPs) not included in this trial, within 30 days of trial registration and throughout the duration of the trial, until disease progression.

13. Able to provide written informed consent.

Exclusion Criteria:

1. Received prior second line therapy for their relapsed disease other than local radiotherapy, therapeutic plasma exchange, or dexamethasone (up to a maximum of 200mg is allowed but not within 30 days prior to registration). Radiotherapy sufficient to alleviate or control pain of local invasion is permitted, but must not be within 14 days before registration. Patients who have received hemi-body radiation or similar since relapse will not be eligible.

2. =Grade 2 peripheral neuropathy within 14 days before registration.

3. Known HIV seropositivity.

4. Known resistance, intolerance or sensitivity to any component of the planned therapies.

5. Any medical or psychiatric condition which, in the opinion of the investigator, contraindicates the participant's participation in this study.

6. Previous or concurrent malignancies at other sites (excluding completely resected non-melanoma skin cancer or carcinoma in situ of any type, such as cervical cancer).

7. Pregnant, lactating or breast feeding female participants.

8. Failure to have fully recovered (i.e.Grade 1 or less toxicity) from the reversible effects of prior chemotherapy.

9. Major surgery within 14 days before registration.

10. Central nervous system involvement with myeloma.

11. Ongoing or active infection requiring systemic antibiotic therapy or other serious infection within 14 days before registration.

12. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.

13. Systemic treatment, within 14 days before the first dose of ixazomib with strong CYP3A inducers (e.g. rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.

14. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib, including difficulty swallowing.

15. Patients that have previously been treated with ixazomib or participated in a study with ixazomib whether treated with ixazomib or not.

16. Participant has current or prior hepatitis B or C infection.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Ixazomib, thalidomide, & dexamethasone (ITD) re-induction
4 - 6 ITD 28-day cycles as follows: Ixazomib 4mg capsule on days 1, 8 and 15 Thalidomide 100mg capsule on days 1-28 Dexamethasone 40mg tablets on days 1, 8, 15 and 22
• Conventional autologous stem cell transplant (ASCT-con)
Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.
• Augmented autologous stem cell transplant (ASCT-aug)
Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.
• ITD consolidation and ixazomib maintenance vs. No further therapy
Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression. Participants randomised to ITD consolidation and ixazomib maintenance will receive: Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression.

Locations

Country	Name	City	State
United Kingdom	Aberdeen Royal Infirmary	Aberdeen
United Kingdom	Monklands Hospital	Airdrie
United Kingdom	University Hospital Ayr	Ayr
United Kingdom	Barnsley Hospital	Barnsley
United Kingdom	Basingstoke & North Hampshire Hospital	Basingstoke
United Kingdom	Royal United Hospital	Bath
United Kingdom	Good Hope Hospital	Birmingham
United Kingdom	Heartlands Hospital	Birmingham
United Kingdom	Queen Elizabeth Hospital	Birmingham
United Kingdom	Blackpool Victoria Hospital	Blackpool
United Kingdom	Pilgrim Hospital	Boston
United Kingdom	Royal Bournemouth Hospital	Bournemouth
United Kingdom	Bradford Royal Infirmary	Bradford
United Kingdom	Bristol Haematology & Oncology Centre	Bristol
United Kingdom	Southmead Hospital	Bristol
United Kingdom	Queen's Hospital	Burton Upon Trent
United Kingdom	Addenbrooke's Hospital	Cambridge
United Kingdom	St Helier Hospital	Carshalton
United Kingdom	Cheltenham General Hospial	Cheltenham
United Kingdom	Countess of Chester Hospital	Chester
United Kingdom	Chesterfield Royal Hospital	Chesterfield
United Kingdom	St Richards Hospital	Chichester
United Kingdom	University Hospital Coventry	Coventry
United Kingdom	Royal Derby Hospital	Derby
United Kingdom	Dewsbury Hospital	Dewsbury
United Kingdom	Russells Hall Hospital	Dudley
United Kingdom	Ninewells Hospital	Dundee
United Kingdom	Hairmyres Hospital	East Kilbride
United Kingdom	Western General Hospital	Edinburgh
United Kingdom	Beatson Cancer Centre	Glasgow
United Kingdom	New Victoria Hospital	Glasgow
United Kingdom	Gloucestershire Royal Hospital	Gloucester
United Kingdom	Grantham and District Hospital	Grantham
United Kingdom	Diana Princess of Wales Hospital	Grimsby
United Kingdom	Calderdale Royal Hospital	Halifax
United Kingdom	Harrogate District Hospital	Harrogate
United Kingdom	Huddersfield Royal Infirmary	Huddersfield
United Kingdom	Castle Hill Hospital	Hull
United Kingdom	Raigmore Hospital	Inverness
United Kingdom	Ipswich Hospital	Ipswich
United Kingdom	Kidderminster Hospital	Kidderminster
United Kingdom	University Hospital Crosshouse	Kilmarnock
United Kingdom	St James's University Hospital	Leeds
United Kingdom	Leicester Royal Infirmary	Leicester
United Kingdom	Lincoln County Hospital	Lincoln
United Kingdom	Royal Liverpool University Hospital	Liverpool
United Kingdom	University Hospital Aintree	Liverpool
United Kingdom	Guys and St Thomas's Hospital	London
United Kingdom	Kings College Hospital	London
United Kingdom	Royal Marsden Hospital	London
United Kingdom	St Barts Hospital	London
United Kingdom	University College London Hospital	London
United Kingdom	Maidstone Hospital	Maidstone
United Kingdom	Manchester Royal Infirmary	Manchester
United Kingdom	The Christie	Manchester
United Kingdom	Borders General Hospital	Melrose
United Kingdom	James Cook University Hospital	Middlesbrough
United Kingdom	Milton Keynes General Hospital	Milton Keynes
United Kingdom	Freeman Hospital	Newcastle
United Kingdom	North Tyneside General Hospital	North Shields
United Kingdom	Norfolk & Norwich University Hospital	Norwich
United Kingdom	Nottingham City Hospital	Nottingham
United Kingdom	Royal Oldham Hospital	Oldham
United Kingdom	Churchill Hospital	Oxford
United Kingdom	Royal Alexandra Hospital	Paisley
United Kingdom	Derriford Hospital	Plymouth
United Kingdom	Pontefract Hospital	Pontefract
United Kingdom	Whiston Hospital	Prescot
United Kingdom	Royal Berkshire Hospital	Reading
United Kingdom	Redditch Hospital	Redditch
United Kingdom	Salford Royal Hospital	Salford
United Kingdom	Salisbury Hospital	Salisbury
United Kingdom	Scunthorpe General Hospital	Scunthorpe
United Kingdom	Royal Hallamshire Hospital	Sheffield
United Kingdom	Southampton General Hospital	Southampton
United Kingdom	St Helens Hospital	St Helens
United Kingdom	Stafford County Hospital	Stafford
United Kingdom	Stepping Hill Hospital	Stockport
United Kingdom	Royal Stoke University Hospital	Stoke-on-Trent
United Kingdom	Sunderland Royal Hospital	Sunderland
United Kingdom	King's Mill Hospital	Sutton In Ashfield
United Kingdom	Singleton Hospital	Swansea
United Kingdom	Musgrove Park Hospital	Taunton
United Kingdom	St George's Hospital	Tooting
United Kingdom	Tunbridge Wells Hospital	Tunbridge Wells
United Kingdom	Pinderfields General Hospital	Wakefield
United Kingdom	Royal Hampshire County Hospital	Winchester
United Kingdom	Wishaw Hospital	Wishaw
United Kingdom	New Cross Hospital	Wolverhampton
United Kingdom	Worcestershire Royal Hospital	Worcester
United Kingdom	Worthing Hospital	Worthing

Sponsors (3)

Lead Sponsor	Collaborator
University of Leeds	Cancer Research UK, Takeda

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Striha A, Ashcroft AJ, Hockaday A, Cairns DA, Boardman K, Jacques G, Williams C, Snowden JA, Garg M, Cavenagh J, Yong K, Drayson MT, Owen R, Cook M, Cook G. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials. 2018 Mar 7;19(1):169. doi: 10.1186/s13063-018-2524-8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Cytogenetics_composite measure	Cytogenetic subgroups will be analysed to explore a number of specific hypotheses, including the effect on PFS, OS, TTP and response (=VGPR vs.	Through study completion, up to 120 months
Primary	Overall response rate	Overall response rate following ASCT will be determined according to the IMWG Uniform Response Criteria for Multiple Myeloma. This endpoint will be defined as a binary dichotomization of response (=VGPR vs	100 days post-ASCT
Primary	Progression-free survival	The influence of a consolidation and maintenance strategy on the Durability of Response (DuR: PFS)	From date of registration to date of disease progression, up to 120 months.
Secondary	Overall survival	Overall survival is defined as the time from randomisation to the consolidation/maintenance part of the trial post-ASCT to death from any cause or last follow-up.	From date of R2 to date of death, up to 120 months
Secondary	Time to disease progression	Time to disease progression is defined as time from randomisation to the consolidation/maintenance part of the trial post-ASCT to first documented evidence of disease progression. Participants who die without disease progression will be censored in the analysis.	From date of registration until date of disease progression, up to 120 months
Secondary	Overall response rate to ITD re-induction	Overall response rate following re-induction will be determined according to the IMWG Uniform Response Criteria for Multiple Myeloma.	At the end of re-induction - after 4-6 re-induction cycles (each cycle is 28 days)
Secondary	Upgrade in response after two cycles of ITD consolidation	Upgrade in response after 2 cycles of ITD consolidation - response rate following ITD consolidation will be determined according to the IMWG Uniform Response Criteria for Multiple Myeloma. This endpoint will be defined as a binary dichotomization of response (=VGPR vs	After 2 cycles of ITD consolidation (each cycle is 28 days)
Secondary	Progression-free survival 2 (PFS2)	Progression-free survival 2 is defined as the time from second randomisation to the consolidation/maintenance part of the trial post-ASCT to second documented disease progression (or the start of next line anti-myeloma treatment), or death from any cause, whichever occurs first. Participants alive and for whom a second progression after second randomisation has not been observed will be censored at the last day they were known to be alive and second progression-free.	Date of R2 to date of second disease progression, up to 120 months
Secondary	Time to next treatment	Time to next line treatment is defined as the time from the date of randomisation to the date of commencement of next line treatment. Participants who do not receive next line treatment will be censored at the date of the last assessment or follow-up visit where they are known to have received no new therapy.	Date of registration to start date of new therapy, up to 120 months
Secondary	Duration of response	Duration of response to protocol treatment is defined from the time of achieving at least a partial response to the date of first documented evidence of disease progression. Participants who die prior to documentation of disease progression will be censored at the date of death. Participants dying from causes not primarily due to progression will also be censored at the date of death. Participants not reaching disease progression at the time of analysis will be censored at the last date known to be progression-free.	Date of achieving at least partial response to date of disease progression, up to 120 months
Secondary	Proportion of patients Minimal Residual Disease negative	Proportion of patients Minimal Residual Disease negative is defined as the proportion of participants with minimal residual disease (MRD) negative as assessed by flow cytometry will be assessed at various points in trial protocol treatment.	Baseline; End of re-induction (after 4-6 cycles of re-induction, each cycle is 28 days); 100 days post-ASCT; After 2 cycles of consolidation (each cycle is 28 days); 8 weeks post-randomisation 2; 12 months post-randomisation 2
Secondary	Continuous Minimal Residual Disease (MRD)	Continuous Minimal Residual Disease (MRD) measurements as assessed by flow cytometry will be assessed at various points in trial protocol treatment.	Baseline; End of re-induction (after 4-6 cycles of re-induction, each cycle is 28 days); 100 days post-ASCT; After 2 cycles of consolidation (each cycle is 28 days); 8 weeks post-randomisation 2; 12 months post-randomisation 2
Secondary	Engraftment kinetics_test	Engraftment kinetics will be summarised based on summaries of stem cell remobilisation protocol and success of remobilisation and stem cell harvest after the completion of ASCT for all participants.	Stem cell harvest; 100 days post-ASCT
Secondary	Incidence of treatment-emergent adverse events (Toxicity and safety)	Toxicity and safety will be reported based on adverse events, as graded by CTCAE V4.03 and determined by routine clinical assessments at each centre.	Baseline; End of each re-induction cycle (each cycle is 28 days); 100 days post-ASCT; End of 2 cycles of consolidation (each cycle is 28 days); 8 weeks post-R2; 3 monthly post-R2 until disease progression; Disease progression, up to 120 months
Secondary	EORTC QLQ-C30_questionnaire	The EORTC QLQ-C30 questionnaire will be used to measure participant-assessed quality of life at registration, post re-induction, 100 days post-ASCT and annually post second randomisation until 24 months post second randomisation, or until disease progression whichever is earlier.	Baseline; End of re-induction (after 4-6 cycles of re-induction, each cycle is 28 days); 100 days post-ASCT; 12 months post-R2; 24 months post-R2
Secondary	EORTC QLQ-MY20_questionnaire	The EORTC QLQ-MY20 questionnaire will be used to measure participant-assessed quality of life at registration, post re-induction, 100 days post-ASCT and annually post second randomisation until 24 months post second randomisation, or until disease progression whichever is earlier.	Baseline; End of re-induction (after 4-6 cycles of re-induction, each cycle is 28 days); 100 days post-ASCT; 12 months post-R2; 24 months post-R2
Secondary	EQ-5D_questionnaire	The EQ-5D questionnaire will be used to measure participant-assessed quality of life at registration, post re-induction, 100 days post-ASCT and annually post second randomisation until 24 months post second randomisation, or until disease progression whichever is earlier.	Baseline; End of re-induction (after 4-6 cycles of re-induction, each cycle is 28 days); 100 days post-ASCT; 12 months post-R2; 24 months post-R2

External Links

•   Myeloma XII protocol paper